Affirmed Gmbh

Affimed Gmbh

Markus Eser

Melvyn Little

Uwe Reusch

Stefan Knackmuss

Kristina Ellwanger

Ivica Fucek

Fabrice Le Gall

Michael Weichel

Eugene Zhukovsky

Fionnuala McAleese-Eser

Thorsten Gantke

Fionnuala Mcaleese-Eser

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

Growing community of inventors

Düsseldorf, Germany

Markus Eser